These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25482746)

  • 1. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
    Chau MM; Kong DC; van Hal SJ; Urbancic K; Trubiano JA; Cassumbhoy M; Wilkes J; Cooper CM; Roberts JA; Marriott DJ; Worth LJ
    Intern Med J; 2014 Dec; 44(12b):1364-88. PubMed ID: 25482746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.
    Worth LJ; Blyth CC; Booth DL; Kong DC; Marriott D; Cassumbhoy M; Ray J; Slavin MA; Wilkes JR
    Intern Med J; 2008 Jun; 38(6b):521-37. PubMed ID: 18588523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021.
    Chau MM; Daveson K; Alffenaar JC; Gwee A; Ho SA; Marriott DJE; Trubiano JA; Zhao J; Roberts JA;
    Intern Med J; 2021 Nov; 51 Suppl 7():37-66. PubMed ID: 34937141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis.
    Reslan Z; Lindsay J; Kerridge I; Gellatly R
    Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.
    Dolton MJ; McLachlan AJ
    Curr Opin Infect Dis; 2014 Dec; 27(6):493-500. PubMed ID: 25229352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.
    van Hal SJ; Gilroy NM; Morrissey CO; Worth LJ; Szer J; Tam CS; Chen SC; Thursky KA; Slavin MA
    Intern Med J; 2014 Dec; 44(12b):1277-82. PubMed ID: 25482740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].
    Scodavolpe S; Quaranta S; Lacarelle B; Solas C
    Ann Biol Clin (Paris); 2014; 72(4):391-404. PubMed ID: 25119797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
    Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
    Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of primary antifungal prophylaxis in patients with haematological malignancies.
    Pagano L; Caira M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive mycoses: strategies for effective management.
    Kontoyiannis DP
    Am J Med; 2012 Jan; 125(1 Suppl):S25-38. PubMed ID: 22196206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.
    Fleming S; Yannakou CK; Haeusler GM; Clark J; Grigg A; Heath CH; Bajel A; van Hal SJ; Chen SC; Milliken ST; Morrissey CO; Tam CS; Szer J; Weinkove R; Slavin MA
    Intern Med J; 2014 Dec; 44(12b):1283-97. PubMed ID: 25482741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR; Slavin MA; Donnelly JP
    Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
    Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
    Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
    Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
    Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of triazole antifungal drugs in patients with cancer.
    Cronin S; Chandrasekar PH
    J Antimicrob Chemother; 2010 Mar; 65(3):410-6. PubMed ID: 20035021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Level of evidence for therapeutic drug monitoring of voriconazole].
    Hulin A; Dailly E; Le Guellec C;
    Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
    Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
    Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.